Jump to content

User talk:Ged UK/Archives/2014/August

Page contents not supported in other languages.
From Wikipedia, the free encyclopedia


Disney Channel (Asia)

Extend PC time? --George Ho (talk) 21:12, 1 August 2014 (UTC)

The Signpost: 30 July 2014

Article Edward Tobinick Please protect. Repeat vandalism, V, NPOV. Peer-reviewed author, his life’s work controversial, randomized double-blind placebo studies in support of his work removed.

The author is his work. Edit removes four randomized double-blind placebo studies that support Dr. Tobinick's invention of etanercept for disk pain relief, and one randomized double-blind placebo study that supports Dr. Tobinick's invention of etanercept for Alzheimer’s Disease:

Randomized, double-blind, placebo-controlled, dose-response, and preclinical safety study of transforaminal epidural etanercept for the treatment of sciatica. Cohen SP, Bogduk N, Dragovich A, Buckenmaier CC 3rd, Griffith S, Kurihara C, et al. Anesthesiology. 2009;110(5):1116–26. http://www.ncbi.nlm.nih.gov/pubmed/?term=cohen+transforaminal+etanercept

Epidural administration of spinal nerves with the tumor necrosis factor-alpha inhibitor, etanercept, compared with dexamethasone for treatment of sciatica in patients with lumbar spinal stenosis: a prospective randomized study. Ohtori S, Miyagi M, Eguchi Y, Inoue G, Orita S, Ochiai N, et al. Spine (Phila Pa 1976).2012;37(6):439–44. http://www.ncbi.nlm.nih.gov/pubmed/?term=ohtori+dexamethasone+etanercept

Randomized, double-blind, placebo-controlled, trial of transforaminal epidural etanercept for the treatment of symptomatic lumbar disc herniation. Freeman BJ, Ludbrook GL, Hall S, Cousins M, Mitchell B, Jaros M, et al. Spine (Phila Pa 1976).2013;38(23):1986–94. http://www.ncbi.nlm.nih.gov/pubmed/?term=freeman+transforaminal+etanercept

Sainoh T, Orita S, Yamauchi K, Suzuki M, Sakuma Y, Kubota G, et al. Intradiscal administration of tumor necrosis factoralpha inhibitor, etanercept, clinically improves intractable discogenic low back pain: a prospective randomized study. In: International society for the study of the lumbar spine 40th annual meeting; Scottsdale (AZ); 2013. http://www.issls.org/wp-content/themes/isslsweb/issls_pdf/oral%20and%20special%20posters.pdf


Dr. Tobinick's invention of etanercept for Alzheimer's Disease is supported in a recent double-blind placebo trial at the University of Southampton in the UK:

Arthritis Drug Shown to Slow Alzheimer’s Down http://medicalxpress.com/news/2014-07-arthritis-drug-shown-alzheimer.html

Thank you. — Preceding unsigned comment added by Rjwrjw100 (talk • contribs) 11:07, 8 August 2014 (UTC)

VisualEditor newsletter—July and August 2014

The VisualEditor team is currently working mostly to fix bugs, improve performance, reduce technical debt, and other infrastructure needs. You can find on Mediawiki.org weekly updates detailing recent work.

Screenshot of VisualEditor's link tool
Dialog boxes in VisualEditor have been re-designed to use action words instead of icons. This has increased the number of items that need to be translated. The user guide is also being updated.

The biggest visible change since the last newsletter was to the dialog boxes. The design for each dialog box and window was simplified. The most commonly needed buttons are now at the top. Based on user feedback, the buttons are now labeled with simple words (like "Cancel" or "Done") instead of potentially confusing icons (like "<" or "X"). Many of the buttons to edit links, images, and other items now also show the linked page, image name, or other useful information when you click on them.

  • Hidden HTML comments (notes visible to editors, but not to readers) can now be read, edited, inserted, and removed. A small icon (a white exclamation mark on a dot) marks the location of each comments. You can click on the icon to see the comment.
  • You can now drag and drop text and templates as well as images. A new placement line makes it much easier to see where you are dropping the item. Images can no longer be dropped into the middle of paragraphs.
  • All references and footnotes (<ref> tags) are now made through the "⧼visualeditor-toolbar-cite-label⧽" menu, including the "⧼visualeditor-dialogbutton-reference-tooltip⧽" (manual formatting) footnotes and the ability to re-use an existing citation, both of which were previously accessible only through the "Insert" menu. The "⧼visualeditor-dialogbutton-referencelist-tooltip⧽" is still added via the "Insert" menu.
  • When you add an image or other media file, you are now prompted to add an image caption immediately. You can also replace an image whilst keeping the original caption and other settings.
  • All tablet users visiting the mobile web version of Wikipedias will be able to opt-in to a version of VisualEditor from 14 August. You can test the new tool by choosing the beta version of the mobile view in the Settings menu.
  • The link tool has a new "Open" button that will open a linked page in another tab so you can make sure a link is the right one.
  • The "Cancel" button in the toolbar has been removed based on user testing. To cancel any edit, you can leave the page by clicking the Read tab, the back button in your browser, or closing the browser window without saving your changes.

Looking ahead

The team posts details about planned work on the VisualEditor roadmap. The VisualEditor team plans to add auto-fill features for citations soon. Your ideas about making referencing quick and easy are still wanted. Support for upright image sizes is being developed. The designers are also working on support for adding rows and columns to tables. Work to support Internet Explorer is ongoing.

Feedback opportunities

The Editing team will be making two presentations this weekend at Wikimania in London. The first is with product manager James Forrester and developer Trevor Parscal on Saturday at 16:30. The second is with developers Roan Kattouw and Trevor Parscal on Sunday at 12:30.

Please share your questions, suggestions, or problems by posting a note at the VisualEditor feedback page or by joining the office hours discussion on Thursday, 14 August 2014 at 09:00 UTC (daytime for Europe, Middle East and Asia) or on Thursday, 18 September 2014 at 16:00 UTC (daytime for the Americas; evening for Europe).

If you'd like to get this newsletter on your own page (about once a month), please subscribe at w:en:Wikipedia:VisualEditor/Newsletter for English Wikipedia only or at Meta for any project. Thank you! Whatamidoing (WMF) (talk) 18:14, 8 August 2014 (UTC)

The Signpost: 06 August 2014

The Signpost: 13 August 2014

PC-protection expiring on or before August 16, 2014

Extend time for Ashoka, Siem de Jong, and Logic? --George Ho (talk) 20:01, 9 August 2014 (UTC)

I've done Logic, but the others seem OK. GedUK  12:31, 18 August 2014 (UTC)

Regarding Page Edward Tobinick

Please revert the protected page to the protected version from August 4, 2014.

The current protected page contains two recent edits by User: Proper Stranger that are in violation of NPOV. As noted on the Talk page, Proper Stranger cherry picked evidence. He removed positive clinical trial results, while leaving other results in. The results of his edits do not present all the significant points of view. His edits fail to conform to Wikipedia NPOV standards.

The doctor’s work with etanercept is an issue of public importance. It is unconscionable that evidence was removed, that all significant views are not presented.

The page without all the evidence should not be the protected page.

If this request to revert the protected page to the protected version from August 4, 2014, is denied, please unprotect the page to allow proper editing that observes NPOV. Proper Stranger’s edits of 8 August 2014, included in the current protected version, fail the NPOV standard.

Thank you. — Preceding unsigned comment added by ThirtyCat (talk • contribs) 14:29, 10 August 2014 (UTC)

Please revert the protected page to the protected version from August 4, 2014.

Comment to Mr. Stradivarius, who denied a request to edit the protected page:

Mr. Stradivarius, I must beg to differ, specifically with two of the points you discuss.

Your suggestion that “detailed information on the clinical trials of etanercept would probably be better off in the Etanercept article” does not describe an issue with this biography. There has been no detailed information on the clinical trials discussed on this page.

This is the biography of a physician who is the inventor of new methods of treatment for neurological disorders. The inventions are why the doctor is notable. You can’t separate the doctor and his inventions. The inventions belong on the page.

While there have been no detailed discussions of clinical trials in this article, note of all trials and news stories should be listed, as they represent the response to these inventions. It is the comprehensive and objective listing that readers want, and expect. It is not NPOV to cherry pick which trials or news stories are included, as Positive Stranger has done.

How is the recent Daily Mail (UK)(this article having been removed by Proper Stranger), “Arthritis drug could also halt Alzheimer's: Treatment found to stop progression of memory loss and poor mood” article not relevant to the topic? The doctor’s invention for the treatment of Alzheimer’s Disease, first reported in 2006, has again been reported on by a major London newspaper, its efficacy being confirmed by a randomized clinical trial. This is not detailed information of a clinical trial that belongs on another page. This is news of the results of a randomized clinical trial, from a major news source, confirming the efficacy of a new method of treatment by the inventor. This is exactly the subject of this article.

The doctor is the holder of the following patents for his inventions: U.S. patents 6419944, 6537549, 7214658, 7629311, 8119127, and 8236306, and Australian patent 758,523. The reporting of all trials and news stories relative to these invented new methods of treatment is exactly the kind of comprehensive, objective evidence the reader wants and deserves, and which is required by NPOV.

Intractable spinal pain is a major public health problem around world. This page discusses a doctor and his new methods of treatment for this health problem. Is there evidence of the efficacy of these inventions? Yes, there is. Four randomized clinical trials (their listings removed by Proper Stranger) report on the efficacy of these treatments.

Proper Stranger removed the listing of trials and news stories that speak to the efficacy of these inventions. He did not remove detailed discussions of the trials themselves, which he argues belong on another page. But mentions of the results of these trials, as a reflection of the inventions, belong on this page. And they must not be selectively edited out.

Regarding your statement that you “don’t think it’s fair to characterize the edits in question as “[removing] positive clinical trial results, while leaving other results in.”” I can’t help but think that’s exactly what was done. Why leave a trial with unfavorable results (Johns Hopkins Walter Reed), but remove the positive trials? Why does the unfavorable trial remain? How is it different?! If the stated purpose is to remove what is relevant to the article’s topic, how is this trial more relevant to the topic than the positive trials? The selective removal of positive trial results appears to be simply because they were positive. This is not NPOV.

The cherry picked version of this article, as edited by Proper Stranger, should not be allowed to mislead and misinform readers for a minute more. Please revert this page to the protected version of 4 August 2014.

Thank you. Rjwrjw100 (talk) 22:29, 10 August 2014 (UTC)

This has been picked up by another admin now, sorry I was on holiday. GedUK  12:34, 18 August 2014 (UTC)

The Signpost: 20 August 2014

The Signpost: 27 August 2014

Retrieved from "https://en.wikipedia.org/w/index.php?title=User_talk:Ged_UK/Archives/2014/August&oldid=624610688"